N
16.37
-0.81 (-4.71%)
| Previous Close | 17.18 |
| Open | 17.18 |
| Volume | 213,694 |
| Avg. Volume (3M) | 185,908 |
| Market Cap | 253,568,032 |
| Price / Sales | 438.73 |
| Price / Book | 1.37 |
| 52 Weeks Range | |
| Earnings Date | 14 Nov 2025 |
| Operating Margin (TTM) | -9,701.19% |
| Diluted EPS (TTM) | -4.36 |
| Total Debt/Equity (MRQ) | 4.01% |
| Current Ratio (MRQ) | 21.03 |
| Operating Cash Flow (TTM) | -69.73 M |
| Levered Free Cash Flow (TTM) | -40.39 M |
| Return on Assets (TTM) | -21.97% |
| Return on Equity (TTM) | -34.96% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Neurogene Inc. | Mixed | Bullish |
AIStockmoo Score
2.6
| Analyst Consensus | 5.0 |
| Insider Activity | 3.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | 2.0 |
| Average | 2.60 |
|
Neurogene Inc is a clinical stage biotechnology company whose objective is to harness the power of gene therapy which is combined with its EXACT gene regulation technology to turn today’s complex devastating neurological diseases into treatable conditions. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 9.28% |
| % Held by Institutions | 115.82% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 200.00 (Canaccord Genuity, 1,121.75%) | Buy |
| Median | 70.00 (327.61%) | |
| Low | 50.00 (LifeSci Capital, 205.44%) | Buy |
| Average | 106.67 (551.62%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 19.85 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Canaccord Genuity | 27 Feb 2026 | 200.00 (1,121.75%) | Buy | 23.49 |
| LifeSci Capital | 26 Jan 2026 | 50.00 (205.44%) | Buy | 19.12 |
| HC Wainwright & Co. | 13 Jan 2026 | 70.00 (327.61%) | Buy | 16.95 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| COBB STUART | 17.64 | - | 16,500 | 291,060 |
| CVIJIC CHRISTINE MIKAIL | 17.64 | - | 22,000 | 388,080 |
| JORDAN JULIE | 17.64 | - | 4,900 | 86,436 |
| MCMINN RACHEL | 17.64 | - | 25,900 | 456,876 |
| Aggregate Net Quantity | 69,300 | |||
| Aggregate Net Value ($) | 1,222,452 | |||
| Aggregate Avg. Buy ($) | 17.64 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MCMINN RACHEL | Officer | 20 Feb 2026 | Acquired (+) | 25,900 | 17.64 | 456,876 |
| CVIJIC CHRISTINE MIKAIL | Officer | 20 Feb 2026 | Acquired (+) | 22,000 | 17.64 | 388,080 |
| JORDAN JULIE | Officer | 20 Feb 2026 | Acquired (+) | 4,900 | 17.64 | 86,436 |
| COBB STUART | Officer | 20 Feb 2026 | Acquired (+) | 16,500 | 17.64 | 291,060 |
| Date | Type | Details |
|---|---|---|
| 04 Feb 2026 | Announcement | Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
| 12 Jan 2026 | Announcement | Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome |
| 05 Jan 2026 | Announcement | Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference |
| 04 Dec 2025 | Announcement | Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |